Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Relay Therapeutics Inc (RLAY)

Relay Therapeutics Inc (RLAY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Relay Therapeutics Reports Promising Interim Data for RLY-2608 in 2L PI3Kα-Mutated Metastatic Breast Cancer

Relay Therapeutics reports positive interim data for RLY-2608 in metastatic breast cancer, supporting a pivotal study in 2025.Quiver AI SummaryRelay Therapeutics, Inc. has announced updated interim clinical...

RLAY : 4.16 (-2.35%)
Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival

RLAY : 4.16 (-2.35%)
Relay Therapeutics to Present Updated Clinical Data for RLY-2608 at San Antonio Breast Cancer Symposium

Relay Therapeutics will present updated clinical data for RLY-2608 in advanced breast cancer at the San Antonio Symposium.Quiver AI SummaryRelay Therapeutics, a clinical-stage precision medicine company,...

RLAY : 4.16 (-2.35%)
Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium

RLAY : 4.16 (-2.35%)
Relay Therapeutics and Elevar Therapeutics Announce Global Licensing Agreement for Lirafugratinib, a Potential Best-in-Class FGFR2 Inhibitor

Elevar Therapeutics secures global rights to develop lirafugratinib, a promising FGFR2 inhibitor, with potential milestone payments for Relay Therapeutics.Quiver AI SummaryRelay Therapeutics and Elevar...

RLAY : 4.16 (-2.35%)
Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors

RLAY : 4.16 (-2.35%)
Relay Therapeutics to Participate in Upcoming Investor Conferences

RLAY : 4.16 (-2.35%)
Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights

RLAY : 4.16 (-2.35%)
Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024

RLAY : 4.16 (-2.35%)
Why Relay Therapeutics Plummeted by Nearly 14% Today

Investors weren't happy with the company's latest effort at capital-raising.

GS : 566.10 (+2.19%)
BAC : 44.17 (+1.82%)
SF : 104.49 (+2.17%)
RLAY : 4.16 (-2.35%)

Barchart Exclusives

Scalp a 47% Payout by the End of This Week with Micron (MU) Call Spreads
Yes, there are serious questions about MU stock following the underlying company’s disappointing earnings but a steady march is all options traders need. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar